Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Keros Therapeutics (KROS) Leases (2019 - 2025)

Keros Therapeutics filings provide 7 years of Leases readings, the most recent being $16.8 million for Q4 2025.

  • On a quarterly basis, Leases fell 12.52% to $16.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.8 million, a 12.52% decrease, with the full-year FY2025 number at $16.8 million, down 12.52% from a year prior.
  • Leases hit $16.8 million in Q4 2025 for Keros Therapeutics, down from $17.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $19.8 million in Q3 2024 to a low of $447000.0 in Q3 2022.
  • Median Leases over the past 5 years was $15.2 million (2023), compared with a mean of $10.5 million.
  • Biggest five-year swings in Leases: plummeted 36.14% in 2022 and later soared 3405.37% in 2023.
  • Keros Therapeutics' Leases stood at $1.1 million in 2021, then skyrocketed by 1343.3% to $15.4 million in 2022, then fell by 0.43% to $15.3 million in 2023, then rose by 25.54% to $19.3 million in 2024, then fell by 12.52% to $16.8 million in 2025.
  • The last three reported values for Leases were $16.8 million (Q4 2025), $17.5 million (Q3 2025), and $18.1 million (Q2 2025) per Business Quant data.